Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in australian patients: A cross-sectional, multicenter study

Clinical Therapeutics

Volumn 32, Issue 7, 2010, Pages 1329-1342

  Standfield, Lachlan ^a   Norris, Sarah ^a   Harvey, Charles ^a   Elliot, Lisa ^a   Riordan, John ^b   Hall, Stephen ^c   Day, Richard ^d   Nash, Peter ^e   Thirunavukkarasu, Krishan ^f   Robertson, James ^f   Palmer, Trish ^f  

^a Health Technology Analysts Pty Ltd   (Australia)

^b Illawarra Rheumatology   (Australia)

^c CABRINI INSTITUTE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f SLR Consulting Australia Pty Ltd   (Australia)

Author keywords

BDMARD; EQ 5D; HAQ; HUI3; Rheumatoid arthritis; Utility

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; ARTICLE; AUSTRALIA; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS;

AGED; ARTHRITIS, RHEUMATOID; AUSTRALIA; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 77955253768     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.07.006     Document Type: Article

References (12)

1. Kobelt G, Jönsson B The burden of rheumatoid arthritis and access to treatment: Outcome and cost-utility of treatments. Eur J Health Econ. 2008, 8(Suppl 2):95-106.
2. Pharmaceutical Benefits Schedule: Etanercept Australian Government Department of Health and Ageing, Accessed July 7, 2010. http://www.pbs.gov.au./html/healthpro/search/results?term=etanercept&scope=PBS+STATIC+WEB+NEWS&form-type=simple.
3. Kind P The EuroQol instrument: An index of health-related quality of life. Quality of Life and Pharmacoeconomics in Clinical Trials 1996, Lippincott-Raven, Philadelphia, Pa. 2nd ed. B. Spilker (Ed.).
4. Feeny D, Furlong W, Boyle M, Torrance GW Multiattribute health status classification systems. Health Utilities Index. PharmacoEconomics. 1995, 7:490-502.
5. Fries JF, Spitz P, Kraines RG, Holman HR Measurement of patient outcome in arthritis. Arthritis Rheum. 1980, 23:137-145.
6. Prevoo MLL, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:44-48.
7. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 system. Med Care. 2002, 40:113-128.
8. Dolan P, Gudex C, Kind P, Williams A A social tariff for EUROQol: Results from a UK general population survey. Centre for Health Economics, The University of York Accessed June 25, 2010. http://www.york.ac.uk/inst/che/pdf/DP138.pdf.
9. Dolan P Modeling valuations for EuroQol health states. Med Care. 1997, 35:1095-1108.
10. Cohen J Statistical Power Analysis for the Behavioural Sciences 1988, L. Erlbaum Associates, Hillside, NJ. 2nd ed.
11. Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005, 60:1571-1582.
12. Shanahan EM, Smith MD, Roberts-Thomson L, et al. The effect of rheumatoid arthritis on personal income in Australia. Intern Med J. 2008, 38:575-579.